Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: Do different dosages of metformin account for different clinical and biochemical outcomes in women with polycystic ovary syndrome (PCOS) and do basal anthropometric and metabolic characteristics of the patients provide any indications regarding the dose required to reach the target effect? SUMMARY ANSWER: Different doses of metformin exerted the same effects on clinical, biochemical and metabolic parameters in patients affected by PCOS. WHAT IS KNOWN AND WHAT THIS PAPER ADDS: Since the insulin-sensitizing agents came into use in the management of PCOS, metformin has shown a positive benefits-risks ratio. Nonetheless, therapeutic schedules are not well standardized. This is the first study which systematically analyses the effect of different doses of metformin on clinical, hormonal and metabolic features of PCOS. On the basis of our results, higher doses are no more effective than lower doses. DESIGN: A multicentric cohort prospective study. A total of 250 PCOS women were enrolled, 49 lost to follow-up. Menstrual cyclicity, hormonal assays, oral glucose tolerance test, lipid profile and ultrasonographic pelvic examination were evaluated at the baseline and after 6 months of metformin treatment at different doses (1000, 1500 and 1700 mg). PARTICIPANTS AND SETTING: A total of 201 PCOS patients completed the study without protocol violations in three university hospitals: seventy-three patients from Centre A (treated with metformin 500 mg twice a day), 60 patients from Centre B (treated with metformin 500 mg three times a day) and 68 patients from Centre C (treated with metformin 850 mg twice a day). MAIN RESULTS AND THE ROLE OF CHANCE: Metformin exerted an overall positive effect on the clinical and endocrine-metabolic features of PCOS. The degree of these effects was independent of the administered dosage in every range of basal body mass index (BMI). When patients were stratified according to their insulinaemic status, scattered inter-doses differences were found in some of the outcome measures. Patients who exhibited an increase of >2 menstrual cycles/year were considered as responders to treatment. Responders had a higher basal BMI than non-responders and showed a greater reduction in plasma testosterone levels after metformin treatment, but other outcome measures did not differ significantly. Total insulin secretion in the 180 min following the glucose tolerance test before metformin treatment (basal AUC-I) was significantly correlated with the decrease in insulin secretion induced by metformin in both the whole group and in responders, but only correlated with the variation in the number of cycles in responders. BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION: The different doses were administered in different centres, and between-centre variation is a potential confounding factor. GENERALIZABILITY TO OTHER POPULATIONS: The paradigm of using the minimum effective dose of metformin could be pursued in other pathological conditions characterized by insulin resistance. STUDY FUNDING/COMPETING INTEREST(S): No funding or competing interests to declare.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, metformin may induce mild to severe gastrointestinal side effects such as nausea, diarrhea, vomiting, and flatulence [11].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [11]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 3×
“The evaluation of insulin sensitivity was made by the homeostatic index (HOMA), which was calculated as follows: HOMA 1⁄4 [fasting insulin (mU/ ml) × fasting glucose (mmol/l)/22, 5] (Matthews et al., 1985).”
MethodInfluentialClassification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 2×
“50% of PCOS women, is the most important determinant of insulin resistance and hyperinsulinaemia, which, nevertheless, also affects 30% of normal weight subjects (Ciampelli and Lanzone, 1998) The high circulating levels of insulin act at various levels of the hypothalamic–pituitary–ovarian axis, as well as on the hepa…”
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027 · cited 1×
“The most commonly reported side effects are nausea, vomiting and gastrointestinal distress, such as diarrhoea, flatulence and abdominal discomfort (Legro et al., 2007; Tang et al., 2012).”
BackgroundPrevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 1×
“Since the first report in 1994 (Velazquez et al., 1994), .500 original studies on metformin administration in PCOS have been published: most of them reported an improvement in insulin sensitivity, body mass index (BMI) and menstrual pattern, and a decrease in androgen levels (Moghetti et al., 2000).”
BackgroundNestler, J. E., Jakubowicz, D. J., Evans, W. S., & Pasquali, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382603 · Cited by 784 · cited 2×
“This finding is in line with some and in contrast to other studies in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely…”
BackgroundResultSelf-citationNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · cited 1×
“…and in contrast to other studies in the literature: some authors, indeed, documented that metformin may restore ovarian function regardless of BMI (Nestler and Jakubowicz, 1996; Nestler and Jakubowicz, 1997; Nestler et al., 1998), whilst others reported that lower BMI was more likely associated…”
ResultTang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Research works printed but not linked: 1
- Moghetti, 2000, Journal of Clinical Endocrinology & Metabolism, 85, 139, 10.1210/jc.85.1.139 · doi:10.1210/jc.85.1.139 · Paper page
Cited by
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“However, metformin may induce mild to severe gastrointestinal side effects such as nausea, diarrhea, vomiting, and flatulence [11].”
BackgroundXing, C., Zhang, J., Zhao, H., & He, B. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s344542 · Cited by 118
“The observed poor compliance has prompted clinicians worldwide to find new ways to treat PCOS.(79) Table 1 Characteristics of the Included RCTs of Intervention on Changes of Serum SHBG”
BackgroundFavourable metabolic effects of a eucaloric lower‐carbohydrate diet in women with PCOS
Gower, B. A., Chandler‐Laney, P. C., Ovalle, F., Goree, L. L., Azziz, R., Desmond, R. A., Granger, W. M., Goss, A. M., & Bates, G. W. (2013) · Clinical Endocrinology · doi:10.1111/cen.12175 · Cited by 108
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
“However, its use may be limited by significant side effects such as nausea, vomiting, and gastrointestinal discomfort [8].”
BackgroundMetformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 87
“Metformin affects the cardiometabolic parameters independent of the dosage administered [39].”
Background
Metadata
- Authors
- Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A.
- Affiliations
- University of Cagliari (IT)
- Università Cattolica del Sacro Cuore (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Corresponding author
- Romualdi, D.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-10
- Volume
- 27
- Issue
- 10
- Pages
- 3057-3066
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2155450883
- Cited by
- 48
- References
- 41
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 7 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, polycystic ovary syndrome, dose-response relationship, insulin sensitizers, menstrual cyclicity, insulin resistance, insulin secretion, testosterone, body mass index, oral glucose tolerance test, lipid profile, insulin-sensitizing therapy, predictors of treatment response, dose standardization
- MeSH terms
- Adult, Dose-Response Relationship, Drug, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Menstrual Cycle, Metformin, Polycystic Ovary Syndrome, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. https://app.cochat.ai/papers/10.1093/humrep/des262
- The paper
- Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A. (2012). Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. Human Reproduction. https://doi.org/10.1093/humrep/des262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.